Bingyi Lin

Zhejiang Provincial Key Laboratory Of Pancreatic Disease
Hangzhou, 310003, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Core Fucosylation Represses SMURF1-Dependent Degradation of CD47 to Promote Tumor Immune Evasion.

Core Fucosylation Represses SMURF1-Dependent Degradation of CD47 to Promote Tumor Immune Evasion.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: August 30, 2025

O-GlcNAcylation of UGDH regulates its activity and remodels the extracellular matrix to facilitate tumor growth.

O-GlcNAcylation of UGDH regulates its activity and remodels the extracellular matrix to facilitate tumor growth.

Journal: Cell death and differentiation
Published: January 31, 2025

O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer.

O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: October 24, 2024

Corrigendum to "Enzyme-responsive multifunctional peptide coating of gold nanorods improves tumor targeting and photothermal therapy efficacy" [Acta Biomaterialia 2019, 86, 363-372].

Corrigendum to "Enzyme-responsive multifunctional peptide coating of gold nanorods improves tumor targeting and photothermal therapy efficacy" [Acta Biomaterialia 2019, 86, 363-372].

Journal: Acta biomaterialia
Published: September 05, 2024

Mina53 catalyzes arginine demethylation of p53 to promote tumor growth.

Mina53 catalyzes arginine demethylation of p53 to promote tumor growth.

Journal: Cell reports
Published: May 07, 2024

The OGT-c-Myc-PDK2 axis rewires the TCA cycle and promotes colorectal tumor growth.

The OGT-c-Myc-PDK2 axis rewires the TCA cycle and promotes colorectal tumor growth.

Journal: Cell death and differentiation
Published: December 12, 2023

Sialic Acid-Modified O-GlcNAc Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma.

Sialic Acid-Modified O-GlcNAc Transferase Inhibitor Liposome Presents Antitumor Effect in Hepatocellular Carcinoma.

Journal: Molecular pharmaceutics
Published: November 23, 2023

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation.

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 21, 2023

SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.

SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.

Journal: Cells
Published: November 13, 2022

O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling.

O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 03, 2022

One-Step Enzymatic Labeling Reveals a Critical Role of O-GlcNAcylation in Cell-Cycle Progression and DNA Damage Response.

One-Step Enzymatic Labeling Reveals a Critical Role of O-GlcNAcylation in Cell-Cycle Progression and DNA Damage Response.

Journal: Angewandte Chemie (International ed. in English)
Published: August 03, 2021

Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.

Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.

Journal: Technology in cancer research & treatment
Published: December 14, 2020
Showing 1-12 of 25

Last Updated: 09/26/2026